Viatris Inc. (NASDAQ:VTRS) is one of the 10 Best Stocks Under $20 to Buy According to Hedge Funds. On February 27, UBS raised its price target on Viatris Inc. (NASDAQ:VTRS) from $18 to $20 and maintained a Buy rating. UBS said the company achieved expected cost-saving targets and the company’s fiscal year 2026 guidance came in above analysts’ consensus expectations.
UBS said that it is focused on Viatris Inc.’s (NASDAQ:VTRS) investor event scheduled for March 19. The firm believes the event could help outline a foundation for the company that supports long-term mid-single-digit revenue growth targets. UBS also believes that the company can deliver EPS growth at a compound annual growth rate in the teens during its next growth phase, which could lead to a higher valuation multiple for the stock. This view is supported by Viatris Inc.’s (NASDAQ:VTRS) announcement of cost-saving initiatives.
Earlier, on February 26, BofA also raised its price target on Viatris Inc. (NASDAQ:VTRS) from $10 to $12 but maintained its Underperform rating on the stock.
The research firm updated its financial model to include Viatris Inc.’s (NASDAQ:VTRS) announced cost-cutting efforts. The company plans to achieve about $400 million in net cost reductions over three years. Roughly half of the savings are expected to come from lowering the cost of goods sold.
Viatris Inc. (NASDAQ:VTRS) is a global healthcare company focused on providing access to generic and brand-name medicines across various therapeutic areas.
While we acknowledge the potential of VTRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Under-the-Radar Stocks to Buy According to Hedge Funds and 15 AI Stocks With Explosive Growth Potential.
Disclosure: None. Follow Insider Monkey on Google News.
